The development of antiplatelet drugs that interfere with the interaction of platelet receptors with von Willebrand factor (VWF) may provide the basis for new therapeutic strategies that will selectively inhibit arterial thrombosis without interfering with normal hemostasis [190]. This evidence concerns the gene VWF and Arterial thrombosis.